VanEck Biotech ETF (BBH) Expected Move

Expected move estimates the probable price range for a given period based on at-the-money options pricing. It reflects the market consensus for volatility over the selected timeframe.

VanEck Biotech ETF (BBH) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $369.1M, listed on NASDAQ, carrying a beta of 0.60 to the broader market. VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. public since 1999-11-23.

Snapshot as of May 15, 2026.

Spot Price

$182.24

Expected Move

6.3%

Implied High

$193.68

Implied Low

$170.80

Front DTE

34 days

As of May 15, 2026, VanEck Biotech ETF (BBH) has an expected move of 6.28%, a one-standard-deviation implied price range of roughly $170.80 to $193.68 from the current $182.24. Expected move is derived from at-the-money straddle pricing and represents the market's pricing of a ±1σ move. Roughly 68% of outcomes should fall within this range under lognormal assumptions, though empirical markets have fatter tails.

BBH Strategy Sizing to the Expected Move

With VanEck Biotech ETF pricing an expected move of 6.28% from $182.24, risk-defined strategies sized to the implied range structurally target the modal outcome distribution. Iron condors with wings at the ±1σ expected move boundaries collect premium against the ~68% probability that spot stays inside the range under lognormal assumptions; strangles set wider at ±1.5σ or ±2σ target the tails but pay smaller per-trade premium. Long-vol structures (long straddles, ratio backspreads) profit when realized move exceeds the implied move, the inverse trade: they bet against the lognormal assumption itself, capitalizing on the empirically fatter equity-return tails.

Learn how expected move is reported and how to read the data →

Per-expiration expected move for BBH derived from ATM implied volatility at each listed expiration. Implied high/low bounds are computed as $182.24 × (1 ± expected move %). One standard-deviation range under lognormal assumptions, roughly 68% of outcomes fall inside.

Frequently asked BBH expected move questions

What is the current BBH expected move?

As of May 15, 2026, VanEck Biotech ETF (BBH) has an expected move of 6.28% over the next 34 days, implying a one-standard-deviation price range of $170.80 to $193.68 from the current $182.24. The expected move is derived from at-the-money straddle pricing and represents the market consensus for a ±1σ price move.

What does the BBH expected move mean for traders?

Roughly 68% of outcomes should fall within ±1 expected move and 95% within ±2 under lognormal assumptions, though equity returns have empirically fatter tails than log-normal predicts. Strategies sized to the expected move (iron condors at ±1σ, strangles at ±1.5σ) target the typical outcome distribution; strategies that profit from tail moves (long-vol structures, ratio backspreads) target the tails the lognormal model under-prices.

How is BBH expected move calculated?

The expected move displayed here is derived from at-the-money implied volatility scaled to the chosen tenor: expected move % is approximately ATM IV times sqrt(T / 365), where T is days to expiration. An equivalent straddle-based form: the ATM straddle (call + put at the same strike) is roughly sqrt(2/pi) times spot times IV times sqrt(T/365), so the implied one-standard-deviation move is approximately 1.25 times ATM straddle divided by spot. The two formulations agree once the sqrt(2/pi) constant is reconciled.